11,912 reports of this reaction
1.7% of all TOFACITINIB reports
#10 most reported adverse reaction
RASH is the #10 most commonly reported adverse reaction for TOFACITINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 11,912 FDA adverse event reports linking TOFACITINIB to RASH. This represents approximately 1.7% of all 696,662 adverse event reports for this drug.
TOFACITINIB has an overall safety score of 85 out of 100. Patients taking TOFACITINIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for TOFACITINIB, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for TOFACITINIB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 11,912 FDA reports for TOFACITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 1.7% of all adverse event reports for TOFACITINIB, making it a notable side effect.
If you experience rash while taking TOFACITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.